Cognitive Effects of Astaxanthin Pretreatment on Recovery From Traumatic Brain Injury

Chen Fleischmann 1,2,3*, Esther Shohami 4, Victoria Trembovler 4, Yuval Heled 2,5 and Michal Horowitz 3

1 The Institute of Military Physiology, IDF Medical Corps, Tel-Hashomer, Israel, 2 Heller Institute of Medical Research, Sheba Medical Center, Ramat Gan, Israel, 3 Laboratory of Environmental Physiology, Hebrew University, Jerusalem, Israel, 4 Department of Pharmacology, Institute for Drug Research, Hebrew University, Jerusalem, Israel, 5 Kibbutzim College, Tel Aviv, Israel

Traumatic brain injury (TBI), caused by mechanical impact to the brain, is a leading cause of death and disability among young adults, with slow and often incomplete recovery. Preemptive treatment strategies may increase the injury resilience of high-risk populations such as soldiers and athletes. In this work, the xanthophyll carotenoid Astaxanthin was examined as a potential nutritional preconditioning method in mice (sabra strain) to increase their resilience prior to TBI in a closed head injury (CHI) model. The effect of Astaxanthin pretreatment on heat shock protein (HSP) dynamics and functional outcome after CHI was explored by gavage or free eating (in pellet form) for 2 weeks before CHI. Assessment of neuromotor function by the neurological severity score (NSS) revealed significant improvement in the Astaxanthin gavage-treated group (100 mg/kg, ATX) during recovery compared to the gavage-treated olive oil group (OIL), beginning at 24 h post-CHI and lasting throughout 28 days ($p < 0.007$). Astaxanthin pretreatment in pellet form produced a smaller improvement in NSS vs. posttreatment at 7 days post-CHI ($p < 0.05$). Cognitive and behavioral evaluation using the novel object recognition test (ORT) and the Y Maze test revealed an advantage for Astaxanthin administration via free eating vs. standard chow during recovery post-CHI (ORT at 3 days, $p < 0.035$; improvement in Y Maze score from 2 to 29 days, $p < 0.02$). HSP profile and anxiety (open field test) were not significantly affected by Astaxanthin. In conclusion, astaxanthin pretreatment may contribute to improved recovery post-TBI in mice and is influenced by the form of administration.

Keywords: astaxanthin, traumatic brain injury (TBI), cognitive tests, neurological severity score (NSS), Y maze, object recognition test (ORT), nutritional supplementation Astaxanthin pretreatment and TBI recovery

INTRODUCTION

Traumatic brain injury (TBI), caused by mechanical impact to the brain, is a leading cause of death and disability among young adults (1). Soldiers (2) and athletes (3), exposed to rigorous conditions and combat hazards, face a high risk of sustaining TBI. Wartime TBI is often caused by blast or concussive injury: a non-penetrating closed head injury (CHI). Complications include sleep disorders (4), anxiety and depression (5), chronic pain (6), memory and other cognitive impairments (7), increased risk of posttraumatic stress disorder (8, 9), and behavioral (2), sensory
(10, 11), and immune disruptions (12). The mechanical brain trauma causes the accumulation of harmful mediators, such as reactive oxygen species (ROS) (13, 14), cytokines, free fatty acids, and excitatory amino acids leading to widespread cell death, through a cytotoxic cascade, which is the driving force to ensuing damage, morbidity, and disability (15). Physiological and psychological stress existing at the time of injury have a profound effect on its outcome (16, 17).

The prophylactic approach to TBI treatment has been extensively explored by pre-treatment with mild stress to induce increased resilience to injury. Limited success was attained with ischemia (18), hypothermia (19), heat stress (20, 21), endotoxin exposure (22), hypoxia (23), and heat acclimation (24, 25). Other preemptive methods utilize hyperbaric oxygen (26, 27), subtoxic doses of chemicals such as 3-nitropropionic acid, and pharmaceuticals including erythromycin, kanamycin, acetylsalicylic acid, 2-deoxyglucose, N-methyl-D-aspartate (NMDA) receptor antagonists (28), low-dose NMDA (29, 30), and even ethanol (31). Their potential adverse effects for long-term prophylaxis in high-risk populations have led to a search for safer substances, particularly nutraceuticals such as omega 3 (32). Astaxanthin is a xanthophyll carotenoid prevalent in marine organisms, approved for human consumption as a safe food supplement (33, 34). Astaxanthin assists in maintaining the integrity of cellular membranes by preventing lipid peroxidation (35). Many health-related benefits have been attributed to Astaxanthin (36–46). Astaxanthin was shown to be effective as a preemptive treatment to different stressors such as exercise in rodents (47, 48), heat-related injury (49), and ischemia–reperfusion injuries (IRIs) (50–54). In a rat model (55), Astaxanthin was shown to penetrate the blood–brain barrier (BBB), to reach therapeutic concentrations, and to exert its antioxidant, anti-inflammatory, and neuroprotective effects (56, 57). In a human study, Astaxanthin was demonstrated to improve the cognitive function in the elderly (58). Brain IRI models in Astaxanthin-supplemented rats before (59, 60) or following (61) IRI showed significantly decreased neuronal damage and neurological deficit scores, accompanied by a dose-dependent increase in heat shock protein 32 (HSP32) and HSP70. Heat shock proteins (HSPs) are important markers in the cellular stress response (62) and have valuable functions in neuroinflammation and neuronal survival (63). Recently, Astaxanthin supplementation displayed cognitive benefits when administered to mice following a CHI model. Results displayed advantages for Astaxanthin treatment postinjury in the neurological severity score (NSS), Y Maze, and object recognition test (ORT) (64).

The aim of this study was 2-fold: (1) to investigate the effect of Astaxanthin pre-treatment on HSP dynamics and functional outcome after CHI and (2) to evaluate the effects of Astaxanthin preparations, gavage or free pellet eating, on motor and cognitive function, within 1 month of follow-up after CHI.

**MATERIALS AND METHODS**

**Ethics**

Experimental procedures were approved by the authority for biological and biomedical models ethics committee for animal experimentation of the Hebrew University, Jerusalem, Israel (Approval numbers: MD-13-13734-4 and MD-16-14842-4) and complied with the guidelines of the national research council guide for the care and use of laboratory animals (65).

**Animals**

Male sabra mice aged 5–7 weeks were included. Pre-experiment, all animals were housed in a controlled environment (12–12 h light–dark cycle and 24 ± 1°C). Food (Teklad Global rodent diet no. 2018SC, 18% protein Harlan Teklad, USA, by Envigo, Israel) and water were provided ad libitum. Animal body weight was recorded biweekly.

**Astaxanthin Preparation**

Astaxanthin 1% w/v for gavage was prepared by dissolving Astaxanthin 10% oleoresin (Astapure®; Algatechnologies, Ktora, Israel) in extra virgin olive oil (acidity ≤0.8%, Negba olive press, Revivim, Israel) by a 1:10 ratio. Astaxanthin 1% w/w handmade pellets for free eating were prepared by grinding rodent food pellets (standard chow) to a powder, mixing in the Astaxanthin 10% oleoresin, at a 1:10 ratio (50 g of Astaxanthin 10% oleoresin, 500 g of animal food powder), and wetting with animal drinking water (350 ml). Pellets were prepared, dried, and frozen.

**Closed Head Injury**

A modified weight drop model was used, based on the work of Chen et al. (66), used frequently in both mice (67–70) and rats (71, 72). Briefly, isoflurane-anesthetized animals underwent a midline longitudinal incision to expose the skull, followed by the use of a calibrated weight-drop device, which allowed a Teflon-tipped cone (2 mm diameter, 95 g), to fall over the exposed skull covering the left cerebral hemisphere 1–2 mm lateral to the midline in the mid-coronal plane, to induce a focal injury to the left hemisphere. Sham-treated mice were anesthetized and underwent skin incision, but no CHI was delivered. Following sham or CHI induction, mice were returned to their cages for recovery. Food and water were provided ad libitum.

**Experimental Layout**

The three experimental stages are depicted in Figure 1: the first stage was aimed to determine whether cellular protection by HSP72 immediately following CHI is affected by Astaxanthin pre-supplementation by gavage. The second stage examined neuromotor and short-term memory effects of Astaxanthin supplementation by gavage during 1 month of recovery. The third stage introduced Astaxanthin administration by free eating,
FIGURE 1 | Flow-charts of experimental stages. (A) First stage (preliminary) – HSP72 dynamics post CHI (un-supplemented). (B) First stage – HSP dynamics post CHI (supplemented, by gavage). (C) Second stage – Gavage experiment, long term recovery. (D) Third stage - Pellet experiment, long term recovery.

and additional cognitive tests were performed within 1 month of recovery.

In the first stage, evaluation of left cortical HSP72 protein dynamics by Western immunoblotting was conducted at $t = 0, 4, 8, 24,$ and 48 h in the left, injured, hemisphere of post-CHI or control mice (Figure 1A, $n = 5$ /group). Next, the 4- and 8-h time points were chosen, and animals were administered either Astaxanthin 1% dissolved in olive oil at 100 mg/kg (ATX, $n = 17$) or olive oil (OIL, $n = 17$), at the same volume (0.1 ml/10 g body weight), by gavage for 2 weeks, excluding weekend (10 days) or standard chow ($n = 16$) for 2 weeks and then exposed to CHI or sham surgery (Figure 1B). Animals were sacrificed at 4 or 8 h post-CHI or sham and cortical HSP72, HSP27, HSP90, and HSF1 content in the affected left-brain hemisphere was assessed by Western immunoblotting. In the second stage, animals were administered either Astaxanthin 1% dissolved in olive oil at 100 mg/kg (ATX, $n = 27$), olive oil (OIL, $n = 45$), or normal saline (SAL, $n = 19$) at the same volume (0.1 ml/10 g body weight), by gavage for 2 weeks, excluding weekend (10 days), and then exposed to CHI (Figure 1C). Recovery consisted of 4 weeks of free eating and drinking, with follow-up assessments of the animals’ motor function using the NSS (see below) performed at 1, 24, 48, and 72 h and at 7, 14, 21, and 28 days post-CHI. Cognitive function was assessed by the ORT and Y Maze test performed at 3 and 30 and 2 and 29 days, respectively, post-injury. Anxiety level was assessed by open field (see below) and performed at 2 and 29 days post-injury.

Behavioral Tests

Neurological Severity Score

The NSS for mice as previously described (66, 73–76) was used to evaluate the neuromotor status after CHI. The presence of reflexes and the ability to perform motor and behavioral tasks are scored from 0 to 10, increasing with the severity of dysfunction (73). The rate of recovery is represented by ANSS— the difference between the NSS at any time point and the initial injury severity (1 h post-CHI) (72). A trained technician, blinded to the treatment received by the animals, performed the test. NSS observations were made at 1, 24, 48, and 72 h and at 7, 14, 21, and 28 days post-CHI.

Object Recognition Test for Mice

Based on a test developed by Ennaceur and Delacour (77), and used extensively to assess short-term memory loss by rodents post-CHI (78–81), the ORT relies on the natural tendency of rodents to explore novelty. It was performed as described previously (82) with mild modifications, at 3 and 30 days post-CHI. Briefly, 24 h after a 10-min habituation to the testing environment (a square white Perspex arena of $50 \times 50 \times 30$ cm), the mouse was subjected to the training stage, during which it was free to explore two identical objects for 5 min. Four hours later in the test stage, one object was replaced by a new, unfamiliar
object, and the mouse was again allowed to explore the arena for 5 min. The tests were performed in a quiet room with low light. Cumulative time spent in object-directed exploratory behavior by the mouse at each object (touching, sniffing, scratching, and climbing) was recorded and scored. A preference toward the new unfamiliar object during the test stage is expected in healthy mice, whereas neurologically affected mice lack memory of the familiar object and spend an equal amount of time exploring both the new and familiar objects. The test exploration ratio was calculated as the exploration time of the new object divided by the exploration time dedicated to both objects. The greater this ratio value, the higher the recognition of novelty. The preference index (PI) was calculated as the difference between the exploration time dedicated to the old and new objects, divided by the exploration time dedicated to both objects. The change in exploration ratio (ΔER) represents the difference between the test and baseline part of the test for the changed object. Test results were compared between the treatments at 3 and 30 days post-CHI, during the baseline and test stages.

**Y Maze**

This spatial memory test was described previously (83–85). A maze built of three black Perspex arms at a 120° angle from one another ("start," "other," and "new" arms) is used for two separate attempts: first, the mouse is placed in the maze at the "start" arm and for 5 min, allowed to freely explore the "start" and "other" arms, while the "new" arm remains closed. Two minutes later, the mouse is returned to the maze and allowed to explore all three arms for 2 min. The amount of time spent in each arm is documented. Short-term memory of recognition is reflected by the novelty ratio (NR), calculated as the amount of time spent in the new arm relative to the total amount of time spent in the "other" plus "new" arms. The discrimination index (DI) is calculated as the difference between time spent in the "other" and "new" arms relative to the total amount of time spent in the "other" and "new" arms. The test was performed at 2 and 29 days post-CHI. Higher values of novelty recognition and of discrimination represent better performance of the spatial memory cognitive function.

**Open Field**

The open field test (86) is based on the behavioral tendency of mice in a heightened state of anxiety to refrain from exploring open unprotected areas and remain mainly at the periphery of the arena, whereas animals in a lower state of anxiety will tend to show a higher interest in freely exploring all areas of the arena. Activity level, as expressed by locomotor behavior, is also assessed in this test. The test was performed as previously described (87) with moderate alterations: a square white Perspex box was used as the arena (size, 50 × 50 × 30 cm). A smaller center zone was defined as 50% of the arena. The animal is introduced into the empty arena without previous acclimation and is left to freely explore the arena for 10 min with video monitoring from above. The arena is later analyzed as a periphery (50 × 50 cm) and a central area (50% in size). The test was performed at 2 and 29 days post-CHI. Motion in the arena was captured and analyzed using the Noldus "Ethovision" software, version XT 11, USA. Analyzed parameters included area preference (center vs. periphery), transition between areas, and locomotor activity.

**Animal Sacrifice**

The animals were sacrificed after the recovery period by sedation with isoflurane, followed by decapitation. Brain tissue was promptly removed, separated to the right and left cortex and hippocampus, placed in liquid nitrogen, and then moved to deep freezing at −80°C.

**Western Immunoblotting**

Left cortical tissue was prepared as described previously (88). Protein concentration was quantified by Bradford reagent (Bio-Rad, USA), and 50-μg samples were separated using 12% sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) gel (TGX Fast cast, Bio-Rad, USA) and blotted onto nitrocellulose membranes, which were then blocked with 5% skim milk powder. Blots were probed overnight at 4°C with primary antibodies against HSP72, HSP27, HSP90, and HSF1. Anti-β-actin antibody was used to confirm equal protein loading. Appropriate peroxidase-coupled immunoglobulin G were used as secondary antibodies (1 h, at room temperature). Supplementary Table 1 lists the primary (Supplementary Table S1A) and secondary (Supplementary Table S1B) antibodies used. Membranes were stripped for reprobing when necessary by exposing them to guanidine thiocyanate 4 M solution for 30 s. Reactive bands were visualized using chemiluminescence (EZ-ECL, Biological Industries, Israel) and detected using the Chemidoc imaging system (Bio-Rad, USA). Image lab software was used to measure band pixel density (version 5.1, Bio-Rad, USA), which was normalized to β-actin in the same lane. Four technical repeats were performed for each sample.

**Statistical Analysis**

Data are presented as mean ± standard error. The SPSS program (version 23, USA) was used for statistical analysis. Protein levels from immunoblotting were normalized to actin in the same lane. In the first stage of the experiment, independent samples t-tests were used to assess the significance of difference between average cortical HSP72 protein levels of mice sacrificed at each time point and the control group. In the following stage, left cortical levels of HSPs were analyzed for normality of distribution using the Kolmogorov–Smirnov test by protein, by the stress employed (TBI or sham treatment), and by time post-CHI (4 or 8 h) and then assessed for statistical significance between pre-treatment groups and stress conditions by one-way ANOVA followed by post hoc analysis with Tukey’s test, for normally distributing parameters, or Kruskal–Wallis test followed by Mann–Whitney’s U test for post-hoc analysis for non-normally distributing parameters. Motor and behavioral test results were tested for normality of distribution by the Kolmogorov–Smirnov or Shapiro–Wilks test and evaluated for significance using one-way ANOVA followed by Tukey’s post-hoc analysis, or Mann–Whitney test for normally and non-normally distributing parameters, respectively. A p < 0.05 was considered significant for all comparisons.
RESULTS

No significant difference was observed in the change in body weight between experimental groups in each of the experimental stages (see Supplementary Table S2 for comparison of animal body weights in the free eating stage).

First Stage

HSP Dynamics

Figure 2A demonstrates that CHI leads to a gradual reduction in cortical HSP72 protein level compared to the control in the affected brain hemisphere, which becomes significantly lower 8 h post-CHI and continues until 24 h post-CHI (Figure 2A, p <
Therefore, the 4- and 8-h time points post-CHI were chosen to evaluate the effect of Astaxanthin supplementation by gavage (ATX) on cortical HSPs (Figures 2B1–B4). Pretreatment with ATX displayed a non-significant trend toward recovery of cortical HSP72, while an opposite trend was observed in the OIL-treated group (non-significant). Analysis of HSP27 levels revealed a similar dynamic to that of HSP72 protein levels in the ATX-supplemented group (not statistically significant). In the OIL-treated group HSP27 protein level at 4 and 8 h was significantly higher than that of the un-supplemented group (SCTBI) \( (p < 0.03) \). No significant difference between groups was observed in HSP90 or HSF1 levels.

**Second Stage**

**NSS**

Initial NSS scores (1 h post-CHI) from all the experimental groups indicated moderate brain trauma (6.24 ± 0.11, 6.49 ± 0.11, 6.70 ± 0.19 for the SAL, OIL, and ATX groups, respectively) (Figure 3A1). ∆NSS during recovery in the ATX gavage group (ATX) was found to be significantly higher than that of the
FIGURE 4 | Third stage results. (A) NSS, stage 3 (pellets). NSS and ΔNSS values for stage 3 from 1 h to 28 days post-CHI, n = 15–17 per group; ATXPre+ATXPost – red; ATXPre+SCPost – orange; SCPre+ATXPost – gray; SCPre+SCPost – blue; (A1) NSS values; (A2) ΔNSS. *P < 0.035 between ΔNSS of ATXPre+SCPost and SCPre+ATXPost; **P < 0.05 between ΔNSS of ATXPre+ATXPost and SCPre+ATXPost. (Mann-Whitney U-test). (B) ORT, stage 3 (pellets). Results of the ORT, pellet
OIL gavage group (OIL) at all tested time points post CHI ($p < 0.007$, Figure 3A2) and higher than the saline gavage group (SAL) from 48 h post-CHI until the end of recovery ($p < 0.033$, Figure 3A2).

**ORT**

Figure 3B depicts the exploration ratio (ER) and preference index (PI) at 3 and 30 days, as well as the change (delta, $\Delta$) in ER from baseline to test at 3 and 30 post-CHI. At 3 days post-CHI, $\Delta$ER was significantly higher in the ATX group compared to the SAL group but not significantly higher than that of the OIL group ($p = 0.005$, Figure 3B3). No improvement in ER, PI, or $\Delta$ER was observed with either ATX or OIL supplementation compared to the SAL group at 30 days post-CHI (Figures 3B4–B6).

**Third Stage**

NSS

Figure 4A depicts the NSS score (Figure 4A1) and changes over time ($\Delta$NSS, Figure 4A2) in the third stage. Initial NSS scores (1 h post-CHI) from all the experimental groups indicated moderate brain trauma (6.42 ± 0.14). Astaxanthin in pellet form, both as pre-treatment (ATXpre_SCpost) and the combined pre- and post-CHI treatment (ATXpre_ATXpost), displayed a significantly higher $\Delta$NSS at 7 days, compared to post-CHI supplementation of Astaxanthin in pellet form (SCpre_ATXpost, $p < 0.05$ and $p < 0.035$, respectively, Figure 4A2).

**ORT**

Results of the third stage ORT are presented in Figure 4B, including ER, PI, and $\Delta$ER at 3 and 30 days post-CHI. At 3 days post-CHI, the ER and PI test values of P_Xpre_SCpost_TBI were significantly higher than those of P_SCpre_SCpost_TBI ($p < 0.035$ and $p < 0.03$, respectively). Moreover, all pellet forms of Astaxanthin administration displayed a significantly higher change in recognition rate from baseline to test ($\Delta$ER) than that of the control un-supplemented group (P_SCpre_SCpost_TBI, $p < 0.042$). At 30 days post-CHI, in both the ER and PI graphs, in the P_Xpre_Xpost group, the test score of the TBI-exposed mice was significantly higher than that of the sham-treated mice ($p = 0.005$). Additionally, the ER and PI of the P_SCpre_SCpost_TBI were significantly higher than those of the P_Xpre_Xpost_TBI group ($p < 0.04$), and a significantly higher $\Delta$ER test score was recorded for the TBI-exposed mice in the P_Xpre_Xpost group compared to the sham-treated mice in the same group ($p < 0.05$).

**Y Maze**

The NR and DI at 2 and 29 days post-CHI, as well as the change ($\Delta$) in NR and in DI from 2 to 29 days post-CHI are depicted in Figure 4C. On day 29 post-CHI, 14 mice escaped from the maze: 2 sham-treated mice (ATXpre_ATXpost, n = 1); ATXpre_SCpost, n = 1) and 12 from the group exposed to CHI (ATXpre_SCpost, n = 5; ATXpre_ATXpost, n = 3; SCpre_ATXpost, n = 2; SCpre_SCpost, n = 2). They were removed from statistical analysis. At 29 days post-CHI, the $\Delta$NR and $\Delta$DI of the TBI-exposed ATXpre + ATXpost treatment group were significantly higher than those of the sham-exposed mice in the same treatment group ($p < 0.005$ each). No significant differences were observed between TBI-exposed mice of the different treatment groups at 2 or 29 days.

**Open Field**

Table 1 lists activity measures in the arena. Individual parameters are depicted in Supplementary Figure S2. No significant difference was observed between treatment groups and stress exposures on day 2 or 29 post-CHI. No effect on anxiety was observed.

**DISCUSSION AND CONCLUSIONS**

The current study examined the effects of pre-treatment with Astaxanthin as a protective measure prior to TBI exposure. We have shown that the functional benefits attributed to Astaxanthin as post-injury treatment, previously demonstrated by Ji et al. in both motor and cognitive neuroprotection, as improvements in the NSS, and in the Y Maze and ORT tests, respectively (64), can be expanded to include prophylactic treatment, as demonstrated by the NSS results of the second stage gavage-treated ATX group, who achieved a significant improvement in $\Delta$NSS over the OIL-treated group. ORT results of the gavage stage show a significant advantage for ATX over SAL, though not over OIL at 3 days postinjury. The differences observed in our work between the gavage-treated animal groups who did not receive additional treatment post-injury resulted only from pre-treatment. In the
### TABLE 1 | Open field results (Third stage).

| Parameter                  | Day post | SC pre_SC post | SC pre_ATX1% post | ATX 1% pre_SC post | ATX1% pre_ATX1% post |
|----------------------------|----------|----------------|-------------------|--------------------|-----------------------|
|                            | TBI      | Sham           | TBI               | Sham               |                       |
| Distance moved (cm)        | 2 11     | 4357.73 ± 1214.79 | 3 4525.3 ± 1085.66 | 9 6028.96 ± 2214.35 | 4 5087.71 ± 494.34 |
|                           | 29 12    | 4198.16 ± 1908.46 | 3 6111.96 ± 1890.83 | 8 4403.29 ± 426.65 | 4 4415.03 ± 1115.11 |
| Velocity (cm/s)            | 2 11     | 7.28 ± 2.02     | 3 7.54 ± 1.8      | 9 10.07 ± 3.67     | 4 8.5 ± 0.81          |
|                           | 29 12    | 7 ± 3.17        | 3 10.2 ± 3.15     | 9 7.34 ± 0.7       | 4 7.37 ± 1.86         |
| Time in center (s)         | 2 11     | 69.27 ± 39.48   | 3 63.77 ± 38.05   | 9 66.58 ± 26.27    | 4 68.14 ± 11.2        |
|                           | 29 12    | 42.51 ± 21.87   | 3 52.68 ± 22.99   | 8 64.83 ± 26.69    | 4 43.53 ± 35.62       |
| Time in Periphery (s)      | 2 11     | 530.4 ± 38.96   | 3 536.21 ± 38.24  | 9 532.01 ± 24.84   | 4 530.16 ± 9.01       |
|                           | 29 12    | 556.62 ± 20.86  | 3 546.39 ± 21.88  | 8 535.06 ± 26.64   | 4 555.61 ± 37.1       |
| Activity in arena          | 2 11     | 0.74 ± 0.21     | 3 0.79 ± 0.08     | 9 0.96 ± 0.24      | 4 0.86 ± 0.21         |
|                           | 29 12    | 0.7 ± 0.23      | 3 1.03 ± 0.07     | 8 0.76 ± 0.16      | 4 0.84 ± 0.21         |
| Highly active duration     | 2 11     | 0.16 ± 0.28     | 3 0.31 ± 0.53     | 9 0.11 ± 0.23      | 4 0.23 ± 0.46         |
|                           | 29 12    | 0 ± 0           | 3 0 ± 0           | 8 0 ± 0            | 4 0 ± 0               |
| Moderately active duration | 2 11     | 19.86 ± 24.38   | 3 15.71 ± 12.04   | 9 48.22 ± 50.2     | 4 33.38 ± 36.65       |
|                           | 29 12    | 22.24 ± 23.12   | 3 49.13 ± 31.43   | 8 21.84 ± 19.46    | 4 33.01 ± 27.33       |
| Inactive duration          | 2 11     | 561.56 ± 37.97  | 3 569.43 ± 22.65  | 9 521.17 ± 65.38   | 4 542.81 ± 54.82      |
|                           | 29 12    | 563.3 ± 35.46   | 3 515.19 ± 27.29  | 8 568.24 ± 32.73   | 4 541.77 ± 38.86      |

SC, Standard Chow; ATX1%, Astaxanthin in pellet form; TBI, exposure to traumatic brain injury; Sham, exposure to sham treatment; pre, before exposure; post, after exposure. N is listed in the table. No significant difference was found between groups (ANOVA).
third stage of the study, we have shown that the more natural pellet form of administration used for supplementation conferred a shorter positive neuromotor effect in the NSS and additional cognitive benefits in the ORT and Y Maze tests late into recovery. Figure 5 summarizes the observed effects of Astaxanthin pre-treatment in the current study.

In humans, exposure to TBI induced a rise in brain tissue HSP72 protein levels measured in the initial hours at 10–24 h post-injury (89). An additional study displayed increased HSP72 conducted in the brain tissue from patients that had undergone surgical intervention after TBI (time point not mentioned) (90), suggesting involvement of the stress response, which was also the conclusion drawn by Lai et al. who analyzed cerebrospinal fluid samples of young patients suffering from TBI (91). Increased HSP72 serum levels have been shown to correlate with injury severity and a fatal outcome at 24 h–7 days post-injury in male patients (92). Indeed, upregulation of HSP70 gene expression was observed postmortem in human TBI patients by Michael et al. (93). The opposite was also reported in children from two studies, suggesting that high initial serum HSP72 levels upon arrival to the emergency room are predictive of survival post-TBI (94, 95). Here, we measured HSP72 protein levels in the impacted left cortical tissue to discover a gradual reduction trend, which became significant 8–24 h post-injury, before rising again, suggesting either increased protein utilization within the injured tissue or inhibited transcription in the initial hours post-injury. The underlying mechanisms for Astaxanthin-induced neuroprotection in TBI are complex and span beyond the scope of this work. Nevertheless, the non-significant trend observed toward increased left cortical levels of HSP72 and HSP27, though insufficient to determine HSP involvement at the site of injury, suggests potential influence for Astaxanthin on the HSP dynamics at the site of injury in the initial hours following TBI.

The neuroprotective effect associated with Astaxanthin has been demonstrated in various types of brain injury resilience: recently, in a rat model of subarachnoid hemorrhage, administration of Astaxanthin post-injury attenuated brain injury by improving mitochondrial function and neuronal survival (96), through involvement of sirtuin-1 and inhibition of the Toll-like receptor 4 signaling pathway (97). Similarly, Astaxanthin has been shown to reduce neuronal apoptosis when administered following spinal cord injury in rats (98). Notably, our group demonstrated similar neuroprotective effects, namely reduced apoptosis following CHI in mice in a cross-tolerance mechanism mediated by heat acclimation [Umschweif et al. (24)].

Astaxanthin’s ability to penetrate the BBB, coupled with existing evidence of Astaxanthin’s benefit in brain IRI models, implies a shared underlying mechanism that could potentially contribute to an improved response to the TBI model employed in this study of CHI. Neuronal preservation by Astaxanthin under stress conditions manifested by upregulation of, e.g., cAMP response element-binding protein (CREB) or brain-derived neurotrophic factor (BDNF) was also demonstrated in vitro (99). Glutamate-related excitotoxicity has been prevented by Astaxanthin pre-treatment in rats (100), possibly, through inhibiting endoplasmic reticulum stress caused by calcium influx (101).

The neuromotor manifestation of recovery demonstrated a significant and consistent advantage to ATX supplementation by gavage over OIL in the ΔNSS score ($p < 0.003$) throughout the recovery period. The pellet-fed group ATXpre_ATXpost displayed significant improvement of ΔNSS at 7 days post-CHI when compared to the post-treated SCpre_ATXpost group although for a shorter duration than the gavage form of administration of Astaxanthin (ATX).

A clear cognitive effect for Astaxanthin was shown in the ORT at 3 days for all pellet forms of Astaxanthin vs. SC in the change between the baseline and test stages of the test ΔER. At 30 days of recovery, advantage in both ORT and Y Maze results was apparent only for the pre-and post-treated group exposed to TBI over the sham-treated mice of the same group. This might mean that ongoing treatment during recovery is beneficial for longer lasting cognitive effects. This finding is in accordance with the fact that post-injury gavage-treated animals tested by Ji et al. demonstrated sustained improved effects in both the Y Maze and ORT tests throughout recovery (64).

The open field results suggest no significant change in anxiety.
In conclusion, we have demonstrated the benefit of Astaxanthin pre-treatment prior to exposure to CHI to both neuromotor and cognitive recovery, independent of treatment during recovery. Despite a more pronounced effect on neuromotor recovery conferred by the gavage form of administration, compared to free eating of pellets of Astaxanthin, a significant improvement in cognitive recovery—an important factor of function—was apparent in Astaxanthin administration by free eating. It is our impression that this form of administration is far less stressful for the animals, produces no change in appetite, as seen by the unaffected gain in body weight (Supplementary Table S2), and upon comparison to behavioral effects observed in the Y Maze and ORT tests, is superior to results obtained from the gavage form of administration (data not shown). Further analysis is required to elucidate the mechanism of action behind the different forms of administration and their influence on neuromotor and cognitive function in CHI; however, it was beyond the scope of the current investigation.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

The animal study was reviewed and approved by the authority for biological and biomedical models of The Hebrew University (Approval numbers: MD-13-13734-4 and MD-16-14842-4).

AUTHOR CONTRIBUTIONS

CF contributed to the conception and design of the study, conducted the experiments, analyzed the data, and wrote the manuscript. ES and MH contributed to the conception and design of the study and to data analysis and reviewed the manuscript. VT contributed to conducting the experiments and to data analysis and reviewed the manuscript. YH contributed to the conception of the study and reviewed the manuscript.

FUNDING

Research reported in this publication was supported by the Israel Defense Forces (IDF) Medical Corps and Directorate of Defense Research & Development Israeli Ministry of Defense (IMOD DDR&D), grant numbers 4440518389 and 4440772172.

ACKNOWLEDGMENTS

The authors would like to thank Dr. Alexander Alexandrovich for conducting the closed head injury and neurological severity score follow-up in the study, Dr. Sigal Liraz-Zaltsman for her invaluable expertise and kind guidance on cognitive behavioral animal testing, and Coral Twito for her assistance in the Western immunoblotting part of the work.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fneur.2020.00999/full#supplementary-material

REFERENCES

1. Marklund N, Hillered L. Animal modelling of traumatic brain injury in preclinical drug development: where do we go from here? Br J Pharmacol. (2011) 164:1207–29. doi: 10.1111/j.1476-5381.2010.01163.x
2. Shively SB, Perl DP. Traumatic brain injury, shell shock, and posttraumatic stress disorder in the military–past, present, and future. J Head Trauma Rehabil. (2012) 27:234–9. doi: 10.1097/HTR.0b013e318250e9dd
3. Zazryn TR, McCrory PR, Cameron PA. Neurologic injuries in boxing and other combat sports. Neurol Clin. (2008) 26:257–70. doi: 10.1016/j.ncl.2007.11.004
4. Zeitzer JM, Friedman L, O’Hara R. Insomnia in the context of traumatic brain injury. J Rehabil Res Dev. (2009) 46:827–36. doi: 10.1682/JRRD.2008.08.0099
5. Meehan A, Lewandowski A, Weaver LK, Deru K. Prospective study of anxiety, post-traumatic stress and depression on postural control, gait, otolith and visuospatial function in military service members with persistent post-concussive symptoms. Undersea Hyperbaric Med. (2019) 46:271–87.
6. Nampiaparampil DE. Prevalence of chronic pain after traumatic brain injury: a systematic review. JAMA. (2008) 300:711–9. doi: 10.1001/jama.300.6.711
7. Maruta J, Lee SW, Jacobs EF, Ghajar J. A unified science of concussion. Ann N Y Acad Sci. (2010) 1208:58–66. doi: 10.1111/j.1749-6632.2010.05695.x
8. Vasterling JJ, Verfaellie M, Sullivan KD. Mild traumatic brain injury and posttraumatic stress disorder in returning veterans: perspectives from cognitive neuroscience. Clin Psychol Rev. (2009) 29:674–84. doi: 10.1016/j.cpr.2009.08.004
9. Jaffee MS, Meyer KS. A brief overview of traumatic brain injury (TBI) and post-traumatic stress disorder (PTSD) within the Department of Defense. Clin Neuropsychol. (2009) 23:1291–8. doi: 10.1080/138540409037250
10. Halbauer JD, Ashford JW, Zeitzer JM, Adamson MM, Lew HL, Ysayavage JA. Neuropsychiatric diagnosis and management of chronic sequelae of war-related mild to moderate traumatic brain injury. J Rehabil Res Dev. (2009) 46:757–96. doi: 10.1682/JRRD.2008.08.0119
11. Santhanam P, Meehan A, Orrison WW, Wilson SH, Oakes TR, Weaver LK. Central auditory processing disorders after mild traumatic brain injury. Undersea Hyperbaric Med. (2019) 46:261–9.
12. Das M, Mohapatra S, Mohapatra SS. New perspectives on central and peripheral immune responses to acute traumatic brain injury. J Neuroinflamm. (2012) 9:236. doi: 10.1186/1742-2094-9-236
13. Shohami E, Gati I, Beit-Yannai E, Trembovler V, Cohen R. Closed head injury in the rat induces whole body oxidative stress: overall reducing antioxidant profile. J Neurot. (1999) 16:365–76. doi: 10.1089/neo.1999.16.365
14. Shohami E, Beit-Yannai E, Horowitz M, Cohen R. Oxidative stress in closed-head injury: brain antioxidant capacity as an indicator of functional outcome. J Cereb Blood Flow Metab. (1997) 17:1007–19. doi: 10.1097/00004647-199710000-00002
15. Lu J, Goh SJ, Tng PY, Deng YY, Ling EA, Mookchiala S. Systemic inflammatory response following acute traumatic brain injury. Front Biosci. (2009) 14:3795–413. doi: 10.2741/3489
16. Meyer KS, Marion DW, Coronel H, Jaffee MS. Combat-related traumatic brain injury and its implications to military healthcare. Psychiatr Clin North Am. (2010) 33:783–96. doi: 10.1016/j.psc.2010.08.007
17. Hoffman SW, Harrison C. The interaction between psychological health and traumatic brain injury: a neuroscience perspective. Clin Neuropsychol. (2009) 23:1400–15. doi: 10.1080/1388547090369433

18. Perez-Pinzon MA, Alonso O, Kraydieh S, Dietrich WD. Induction of tolerance against traumatic brain injury by ischemic preconditioning. Neuroreport. (1999) 10:2581–4. doi: 10.1097/00001756-199909290-00014

19. Lotocki G, de Rivero Vaccari JP, Perez ER, Alonso OF, Curbelo K, Keane RW, et al. Therapeutic hypothermia modulates TNFR1 signaling in the traumatized brain via early transient activation of the JNK pathway and suppression of XIAP cleavage. Eur J Neurosci. (2006) 24:2283–90. doi: 10.1111/j.1460-9568.2006.05123.x

20. Duveau V, Arthusaud S, Rougier A, Le Gal La Salle G. Polysialylation of NCAM is upregulated by hyperthermia and participates in heat shock preconditioning-induced neuroprotection. Neurobiol Dis. (2007) 26:385–95. doi: 10.1016/j.nbd.2007.01.007

21. Su Z, Han D, Sun B, Qiu J, Li Y, Li M, et al. Heat stress preconditioning improves cognitive outcome after diffuse axonal injury in rats. J Neurotrauma. (2009) 26:1695–706. doi: 10.1089/neu.2008.0519

22. Longhi L, Gesuete R, Perego C, Ortolano F, Sacchi N, Villa P, et al. Long-lasting protection in brain trauma by endotoxin preconditioning. J Cereb Blood Flow Metab. (2011) 31:1919–29. doi: 10.1038/jcbfm.2011.42

23. Wei IH, Huang CC, Tseng CY, Chang HM, Tu HC, Tsai MH, et al. Therapeutic hypothermia modulates TNFR1 signaling in the traumatized brain via early transient activation of the JNK pathway and suppression of XIAP cleavage. Eur J Neurosci. (2006) 24:2283–90. doi: 10.1111/j.1460-9568.2006.05123.x

24. Umschwert G, Shein NA, Alexandrovich AG, Trevboliver V, Horowitz M, Shohami E. Heat acclimation provides sustained improvement in functional recovery and attenuates apoptosis after traumatic brain injury. J Cereb Blood Flow Metab. (2010) 30:616–27. doi: 10.1038/jcbfm.2009.234

25. Shein NA, Horowitz M, Shohami E. Heat acclimation: a unique model of physiologically mediated global preconditioning against traumatic brain injury. Prog Brain Res. (2007) 161:353–63. doi: 10.1016/S0079-6123(06)61025-X

26. IadHAV V, Ostrowski RP, Tong W, Matus B, Jesunathadas R, Zhang JH. Cyclo-oxygenase-2 mediates hyperbaric oxygen preconditioning-induced neuroprotection in the mouse model of surgical brain injury. Stroke. (2009) 40:3139–42. doi: 10.1161/STROKEAHA.109.549774

27. Hu S, Li F, Luo H, Xia Y, Zhang J, Hu R, et al. Amelioration of rCBF and PbtO2 following TBI at high altitude by hyperbaric oxygen preconditioning-induced neuroprotection. J Neurosci Res. (2010) 88:1329–37. doi: 10.1002/jnr.22300

28. Rejdak R, Rejdak K, Sieklucka-Dziuba M, Stelmasiak Z, Grieb P. Brain protective effects of PBT2 following TBI at high altitude by hyperbaric oxygen preconditioning. Antioxid Redox Signal. (2011) 12:5–7. doi: 10.1089/ars.2010.315

29. Costa T, Constantino LC, Mendonca BP, Pereira JG, Herculano B, Tasca M. Astaxanthin reduces ischemic brain injury in adult rats. FREE J. (2009) 23:1958–68. doi: 10.1096/fo.08-12380

30. Moojen VK, Damiani-Neves M, Bavaresco DV, Pescador BB, Comim CM, Quevedo J, et al. Therapeutic hypothermia modulates TNFR1 signaling in the traumatized brain via early transient activation of the JNK pathway and suppression of XIAP cleavage. Eur J Neurosci. (2006) 24:2283–90. doi: 10.1111/j.1460-9568.2006.05123.x

31. Kim JH, Nam SW, Kim BW, Kim WJ, Choi YH. Astaxanthin improves the proliferative capacity as well as the osteogenic and adipogenic differentiation potential in neural stem cells. Food Chem Toxicol. (2010) 48:1741–5. doi: 10.1016/j.fct.2010.04.002

32. Eklep L, Inaku K, Eklep V. Antioxidant effects of astaxanthin in various diseases—a review. J Mol Pathophysiol. (2018) 7:1–6. doi: 10.5455/jmp.20180627120187

33. Iikeuchi M, Koyama T, Takahashi J, Yazawa K. Effects of astaxanthin supplementation on exercise performance in mice. Biol Pharm Bull. (2006) 29:2106–10. doi: 10.1248/bpb.29.2106

34. Aoi W, Naito Y, Sakuma K, Kuchide M, Tokuda H, Maoka T, et al. Astaxanthin limits exercise-induced skeletal and cardiac muscle damage in mice. Antioxid Redox Signal. (2003) 5:139–44. doi: 10.1089/152576032005223630

35. Namekawa T, Ikeda S, Sugimoto M, Kume S. Effects of astaxanthin-containing oil on development and stress-related gene expression of bovine embryos exposed to heat stress. Reprod Domest Anim. (2010) 45:e387–91. doi: 10.1111/j.1439-0531.2010.01584.x

36. Adluri RS, Thirunavukkarasu M, Zhan L, Mauilik N, Svennevik K, Bagchi M, et al. Cardioprotective efficacy of a novel antioxidant mix vitesapro against ex vivo myocardial ischemia-reperfusion injury. Cell Biochem Biophys. (2011) 67:281–6. doi: 10.1007/s12013-011-9307-0

37. Lamont DA, Lockwood SF, Lucchesi BR. Disodium disuccinate Astaxanthin (Cardax) attenuates complement activation and reduces myocardial injury following ischemia/reperfusion. J Pharmacol Exp Ther. (2005) 314:686–92. doi: 10.1124/jpet.105.087714

38. Gross GI, Lockwood SF, Acute and chronic administration of disodium disuccinate astaxanthin (Cardax) produces marked cardioprotection in dog hearts. Mol Cell Biochem. (2005) 272:221–7. doi: 10.1007/s11010-005-7555-2

39. Curek GD, Cort A, Yuceel G, Demir N, Ozturk S, Elpek GO, et al. Effect of astaxanthin on hematopoietic cell injury following ischemia/reperfusion. Toxicology. (2010) 267:147–53. doi: 10.1016/j.tox.2009.11.003

40. Takizawa Y, Kitazato T, Kishimoto H, Tomita M, Hayashi M. Effects of astaxanthin on spermatogenesis in mice. J Reprod Dev. (2012) 58:1161–7. doi: 10.1254/jrd.58.1161

41. Lauer DA, Lockwood SF, Lucchesi BR. Disodium disuccinate Astaxanthin (Cardax) attenuates complement activation and reduces myocardial injury following ischemia/reperfusion. J Pharmacol Exp Ther. (2005) 314:686–92. doi: 10.1124/jpet.105.087714

42. Gross GI, Lockwood SF. Acute and chronic administration of disodium disuccinate astaxanthin (Cardax) produces marked cardioprotection in dog hearts. Mol Cell Biochem. (2005) 272:221–7. doi: 10.1007/s11010-005-7555-2

43. Curek GD, Cort A, Yuceel G, Demir N, Ozturk S, Elpek GO, et al. Effect of astaxanthin on hematopoietic cell injury following ischemia/reperfusion. Toxicology. (2010) 267:147–53. doi: 10.1016/j.tox.2009.11.003

44. Takizawa Y, Kitazato T, Kishimoto H, Tomita M, Hayashi M. Effects of astaxanthin on spermatogenesis in mice. J Reprod Dev. (2012) 58:1161–7. doi: 10.1254/jrd.58.1161

45. Lauer DA, Lockwood SF, Lucchesi BR. Disodium disuccinate Astaxanthin (Cardax) attenuates complement activation and reduces myocardial injury following ischemia/reperfusion. J Pharmacol Exp Ther. (2005) 314:686–92. doi: 10.1124/jpet.105.087714

46. Gross GI, Lockwood SF. Acute and chronic administration of disodium disuccinate astaxanthin (Cardax) produces marked cardioprotection in dog hearts. Mol Cell Biochem. (2005) 272:221–7. doi: 10.1007/s11010-005-7555-2
56. Galasso C, Oreﬁce I, Pellone P, Cirino P, Miele R, Ianora A, et al. On the Neuroprotective role of astaxanthin: new perspectives? Marine Drugs. (2018) 16:247. doi: 10.3390/md16080247

57. Manabe Y, Komatsu T, Seki S, Sugawara T. Dietary astaxanthin can accumulate in the brain of rats. Biosci Biotechnol Biochem. (2018) 82:1–4. doi: 10.1080/01664328.2018.1439467

58. Katagiri M, Satoh A, Tsuchi S, Shirasawa T. Effects of astaxanthin-rich Haematococcus pluvialis extract on cognitive function: a randomised, double-blind, placebo-controlled study. J Clin Biochem Nutr. (2012) 51:102–7. doi: 10.3164/jcbn.D-11-00017

59. Lu YP, Liu SY, Sun H, Wu XM, Li JJ, Zhu L. Neuroprotective effect of astaxanthin on H(2)O(2)-induced neurotoxicity in vitro and on focal cerebral ischemia in vivo. Brain Res. (2010) 1360:40–8. doi: 10.1016/j.brainres.2010.09.016

60. Pan L, Zhou Y, Li X-F, Wan Q-J, Yu L-H. Preventive treatment of astaxanthin provides neuroprotection through suppression of reactive oxygen species and activation of antioxidant defense pathway after stroke in rats. Brain Res Bull. (2017) 130:211–20. doi: 10.1016/j.brainresbull.2017.01.024

61. Lee DH, Lee YJ, Kwon KH. Neuroprotective effects of astaxanthin in oxygen-glucose deprivation in SH-SYSY cells and global cerebral ischemia in rat. J Clin Biochem Nutr. (2010) 47:121–9. doi: 10.3164/jcbn.10-29

62. Somero GN. The cellular stress response and temperature: Function, regulation, and evolution. J Exp Zool A Ecol Integr Physiol. (2020) 333:379–97. doi: 10.1002/jez.2344

63. Ducay B, Cocho B, Toth ME. Heat-shock proteins in neuroinflammation. Front Pharmacol. (2019) 10:920. doi: 10.3389/fphar.2019.00920

64. Ji X, Peng D, Zhang Y, Zhang J, Wang Y, Gao Y, et al. Astaxanthin improves cognitive performance in mice following mild traumatic brain injury. Brain Res. (2017) 1659:88–95. doi: 10.1016/j.brainres.2016.12.031

65. Council NR. Guide for the Care and Use of Laboratory Animals. National Academies Press (2010).

66. Chen Y, Constantini S, Trembovler V, Weinstock M, Shohami E. An experimental model of closed head injury in mice: pathophysiology, histopathology, and cognitive deﬁcits. J Neurotrauma. (1996) 13:557–68. doi: 10.1089/neu.1996.13.557

67. Shohami E, Cohen-Yeshurun A, Trembovler V, Alexandrovich A, Ryberg E, Greasley MJ. Inosine improves functional recovery after experimental traumatic brain injury. Brain Res. (2008) 1200:296–306. doi: 10.1016/j.brainres.2008.02.022

68. Cohen-Yeshurun A, Trembovler V, Alexandrovich AG, et al. D-cycloserine improves functional recovery and reinstates long-term potentiation (LTP) in a mouse model of closed head injury. FASEB J. (2007) 21:2033–41. doi: 10.1096/f06-7856com

69. Dachir S, Shabashov D, Trembovler V, Alexandrovich AG, Benowitz LI, Shohami E. Inosine improves functional recovery after experimental traumatic brain injury. Brain Res. (2014) 1555:78–88. doi: 10.1016/j.brainres.2014.01.044

70. Baratz R, Rubovitch V, Frenk H, Pick CG. The influence of alcohol on behavioral recovery after mTBI in mice. J Neurotrauma. (2010) 27:555–63. doi: 10.1089/neu.2009.0891

71. Dellu F, Mayo W, Cherkauo J, Le Moal M, Simon H. A two-trial memory task with automated recording: study in young and aged rats. Brain Res. (1992) 588:132–9. doi: 10.1016/0006-8993(92)91352-F

72. Yamada M, Hayashida M, Zhao Q, Shibahara N, Tanaka K, Miyata T, et al. Ameliorative effects of yokukansan on learning and memory deficits in olfactory bulbectomized mice. J Ethnopharmacol. (2011) 135:737–46. doi: 10.1016/j.jep.2011.04.010

73. Walsh RN, Cummins RA. The Open-ﬁeld test: a critical review. Psychol Bull. (1976) 83:482–504. doi: 10.1037/0033-2909.83.3.482

74. Liraz-Zaltsman S, Yaka R, Shabashov D, Shohami E, Biegon A. Neuroinflammation-induced memory deﬁcits are amenable to treatment with D-cycloserine. J Mol Neurosci. (2016) 60:46–62. doi: 10.1007/s12031-016-0786-8

75. Maloyan A, Elir-Beerchoer L, Semenla GL, Gerstenblith G, Stern MD, Horowitz M. HIF-1a-targeted pathways are activated by heat acclimation and contribute to acclimation-ischemic cross-tolerance in the heart. Physiol Genom. (2005) 23:79–88. doi: 10.1152/physiogenomics.00279.2004

76. Seidberg NA, Clark RS, Zhang X, Lai Y, Chen M, Graham SH, et al. Inductions in tactile 72-kDa heat shock protein and the chaperone cofactor BAG-1 in human brain after head injury. J Neurochem. (2003) 84:514–21. doi: 10.1046/j.1471-4159.2003.01547.x

77. Beit-Yannai E, Kohen R, Horowitz M, Trembovler V, Shohami E. Antioxidants attenuate acute toxicity of tumor necrosis factor-alpha induced by brain injury in rat. J Interferon Cytokine Res. (1999) 19:791–5. doi: 10.1089/107999099313640

78. Beni-Adani L, Gozes I, Cohen Y, Assaf Y, Steingart RA, Brenneman DE, et al. A peptide derived from activity-dependent neuroprotective protein (ADNP) ameliorates injury response in closed head injury in mice. J Pharmacol Exp Ther. (2001) 296:57–63.

79. Chen Y, Lomnitski L, Michaelson DS, Shohami E. Motor and cognitive deﬁcits in apolipoprotein E-deficient mice after closed head injury. Neuroscience. (1997) 80:1255–62. doi: 10.1016/S0366-4522(97)00007-9

80. Beit-Yannai E, Kohen R, Horowitz M, Trembovler V, Shohami E. Changes of biological reducing activity in rat brain following closed head injury: a cyclic voltammetry study in normal and heat-acclimated rats. J Cereb Blood Flow Metab. (1997) 17:273–9. doi: 10.1097/00004467-199703000-00004
95. Žurek J, Fedora M. The usefulness of S100B, NSE, GFAP, NF-H, secretagogin and Hsp70 as a predictive biomarker of outcome in children with traumatic brain injury. *Acta Neurochirurg.* (2012) 154:93–103. doi: 10.1007/s00701-011-1175-2

96. Wang Y, Liu Y, Li Y, Liu B, Wu P, Xu S, et al. Protective effects of astaxanthin on subarachnoid hemorrhage-induced early brain injury: Reduction of cerebral vasospasm and improvement of neuron survival and mitochondrial function. *Acta Histochem.* (2018) 121:56–63. doi: 10.1016/j.acthis.2018.10.014

97. Zhang X, Lu Y, Wu Q, Dai H, Li W, Lv S, et al. Astaxanthin mitigates subarachnoid hemorrhage injury primarily by increasing sirtuin 1 and inhibiting the Toll-like receptor 4 signaling pathway. *FASEB J.* (2018) 2018:fj.201800642RR. doi: 10.1096/fj.201800642RR

98. Fakhri S, Dargahi L, Abbaszadeh F, Jorjani M. Astaxanthin attenuates neuroinflammation contributed to the neuropathic pain and motor dysfunction following compression spinal cord injury. *Brain Res Bull.* (2018) 143:217–24. doi: 10.1016/j.brainresbull.2018.09.011

99. Gite S, Ross RP, Kirke D, Guihéneuf F, Aussant J, Stengel DB, et al. Nutraceuticals to promote neuronal plasticity in response to corticosterone-induced stress in human neuroblastoma cells. *Nutrit Neurosci.* (2018) 22:551–68. doi: 10.1080/1028415X.2017.1418728

100. Chang Y, Lu CW, Chen YJ, Lin TY, Huang SK, Wang SJ. Astaxanthin protects against kainic acid-induced seizures and pathological consequences. *Neurochem Int.* (2018) 116:85–94. doi: 10.1016/j.neuint.2018.02.008

101. Lin X, Zhao Y, Li S. Astaxanthin attenuates glutamate-induced apoptosis via inhibition of calcium influx and endoplasmic reticulum stress. *Eur J Pharmacol.* (2017) 806:43–51. doi: 10.1016/j.ejphar.2017.04.008

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.